OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Study ID
- NCT01802684
- Phase
- PHASE2
- Status
- Completed
Conditions
- Unresectable Metastatic Colorectal Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- aflibercept — BIOLOGICALAflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
Study Details
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
Key Dates
- Start date
- May 31, 2013
- Status verified
- Feb 2017
- Primary completion
- Nov 30, 2014
- Completion
- Jun 30, 2016
Study Design
- Enrollment
- 49 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: OPTIMOX-afliberceptInduction therapy (sequence #1) * Regimen : aflibercept + modified FOLFOX7 * Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A) * Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine) * Duration : 6 cycles (3 months) Second phase (sequence #2B) * Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval) * Duration : until PD or limiting toxicity Reintroduction (sequence #3) * Regimen : aflibercept + modified FOLFOX7 * Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4) * Regimen : aflibercept + fluoropyrimidine * Duration : until PD or limiting toxicity
Primary Outcome Measure
Progression free survival at 6 months [ Time Frame: time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed at 6 months. ]
Related Studies
- alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cellsPHASE1 · Recruiting · Celyad Oncology SA · Tampa, Florida
- Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerPHASE1 · Recruiting · Celyad Oncology SA · Jacksonville, Florida
- First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal CancerPHASE1/PHASE2 · Recruiting · Brenus Pharma · Baltimore, Maryland